NCT06255210RecruitingPhase 2
Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma (ESICON)
Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma: a Prospective Umbrella Clinical Study
Source: ClinicalTrials.gov · Last updated 13 Feb 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this clinical trial is to learn about the induction chemotherapy efficacy in olfactory neuroblastoma. The main question it aims to answer is: wether olfactory neuroblastoma patients with different pathology subtypes apply to different induction chemotherapy schemes. Participants will be treated with different chemotherapy schemes, to evaluate the tumor remission rate and long term survival.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- First submitted
- 4 Feb 2024
- Start date
- 1 Mar 2024
- Primary completion date
- 1 Mar 2027
- Lead sponsor
- Hongmeng Yu
- Diseases
- Neuroblastoma
- NCT number
- NCT06255210
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 25
- From 1 Mar 2024 to the primary completion date, 1 Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with uncontrolled concurrent diseases that the researchers believe will interfere with treatment;
Other illness
- Severe neurological or mental illness, including dementia and seizures;
- Uncontrolled active infection;
Other
- Any situation in which the patient may interfere with the compliance or safety during the study;
- Pregnant or lactating women;
- Persons without personal freedom and independent capacity for civil conduct;
- Other situations that are not suitable for joining the group.
Who the study is looking for
- Patients with pathologically confirmed olfactory neuroblastoma;
- Age ≥ 18 years old;
- Dulguerov stage T2-T4;
- Patients who signed the informed consent forms;
- No distant metastasis.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Eye ENT Hospital of Fudan University Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.